Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

NAActive, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 27, 2009

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Liver Cancer
Interventions
OTHER

CT guided percutaneous ablation

Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01494324 - Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome | Biotech Hunter | Biotech Hunter